Synovics Pharmaceuticals, Inc.

OTCPK:SYVC Stock Report

Market Cap: US$3.6k

Synovics Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Es liegen keine ausreichenden Daten über die Leistung von Synovics Pharmaceuticals in den letzten Jahren vor.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Jul 2009

Recent past performance updates

No updates

Recent updates

No updates

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Synovics Pharmaceuticals has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Show section

Revenue & Expenses Breakdown
Beta

How Synovics Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:SYVC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Jul 0919-581

Qualität der Erträge: Unzureichende Daten, um festzustellen, ob SYVC hohe Ertragsqualität hat.

Wachsende Gewinnspanne: Es liegen keine ausreichenden Daten vor, um festzustellen, ob sich die Gewinnspannen von SYVC im letzten Jahr verbessert haben.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Ergebnisentwicklung: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die jährliche Gewinnwachstumsrate von SYVC in den letzten 5 Jahren positiv war.

Beschleunigtes Wachstum: Unzureichende Daten, um das Gewinnwachstum des vergangenen Jahres mit dem 5-Jahres-Durchschnitt von SYVC zu vergleichen.

Erträge im Vergleich zur Industrie: Es liegen keine ausreichenden Daten vor, um festzustellen, ob das Gewinnwachstum von SYVC im vergangenen Jahr über dem Branchendurchschnitt von Pharmaceuticals lag.


Return on Equity

Hohe Eigenkapitalrendite: SYVC hat eine negative Eigenkapitalrendite (0%), da es derzeit unrentabel ist.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.